Working… Menu

Chronic Hepatitis C Non-Responder Study With AdoMet and Betaine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00310336
Recruitment Status : Completed
First Posted : April 3, 2006
Last Update Posted : October 28, 2010
Information provided by:
University Hospital, Basel, Switzerland

Tracking Information
First Submitted Date  ICMJE March 31, 2006
First Posted Date  ICMJE April 3, 2006
Last Update Posted Date October 28, 2010
Study Start Date  ICMJE August 2006
Actual Primary Completion Date August 2009   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 31, 2006)
Sustained response rate
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: March 31, 2006)
Early virologic response after 12 weeks of therapy with PegIntron, Rebetol, AdoMet and betaine.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE Chronic Hepatitis C Non-Responder Study With AdoMet and Betaine
Official Title  ICMJE Chronic Hepatitis C: Treatment of (Peg)Interferon Alpha - Ribavirin Non-Responders With Pegylated Interferon alpha2b, Ribavirin, AdoMet and Betaine
Brief Summary

50-60% of patients with chronic hepatitis C are not cured by treatment with pegylated IFNα plus ribavirin.

Retreatment of non-responders of previous (pegylated) IFNα plus ribavirin therapies with pegylated IFNα plus ribavirin results in a sustained response in less than 10% of the patients.

Extensive analysis of IFNα signaling in cells expressing HCV proteins, in transgenic mice expressing HCV proteins, and in liver biopsies from patients with chronic hepatitis C point to STAT1 methylation as an important posttranslational modification targeted by HCV to inhibit IFNα signaling.

STAT1 methylation can be increased and IFNα can be improved by adding AdoMet and betaine.

The study is designed to test the hypothesis that a combination treatment with pegylated IFNα2b, ribavirin, AdoMet and betaine is superior to the current standard combination therapy with pegylated IFNα plus ribavirin.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Phase 3
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Hepatitis C
Intervention  ICMJE
  • Drug: S-adenosyl-L-methionine
  • Drug: betaine
  • Drug: pegylated interferon alpha2b
  • Drug: ribavirin
Study Arms  ICMJE Not Provided
Publications *

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Completed
Estimated Enrollment  ICMJE
 (submitted: March 31, 2006)
Original Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE September 2009
Actual Primary Completion Date August 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male and female between 18 and 65 years.
  • Non-responders in previous treatments with IFNα plus ribavirin or pegylated IFNα plus ribavirin.
  • Elevated ALT-levels on at least two occasions during >6 months preceding entry.
  • Detection of HCV RNA in serum (PCR).
  • Compensated liver disease (Child-Pugh A) and a Child-Pugh score <5.
  • The following minimal hematologic and biochemical criteria:
  • Hemoglobin for males and females >11g/dl
  • Absolute Neutrophil count >1500 cells/mm3
  • Platelets >75'000/mm3
  • HBs Ag negative.
  • ANA <1:320, and no evidence for autoimmune hepatitis.
  • α-Fetoprotein <50μg/l (when between upper limit of normal and 50μg/l, ultrasonographical exclusion of hepatocellular carcinoma (HCC) is needed).
  • Fasting blood glucose within normal limits, if history of diabetes or hypertension, a pre-therapy ocular examination is indicated.
  • TSH within normal limits or adequately controlled.
  • Negative urine or blood pregnancy test (for women of childbearing potential) documented within the 2-3 week period prior to the first dose of study drug. Additionally, all fertile males and females must be using effective contraception during treatment and during the 6 months after treatment end. This may include, but is not limited to, using birth control pills, IUDs, condoms, diaphragms, or implants, being surgically sterilized, or being in a post-menopausal state.
  • Willingness to give written informed consent and willingness to participate to and comply with the study

Exclusion Criteria:

  • Women with ongoing pregnancy or breast feeding.
  • Positive test at screening for anti-HAV IgM Ab, HBsAg, anti-HBc IgM Ab, HBe Ag.
  • Positive test at screening for HIV.
  • History or other evidence of a medical condition associated with chronic liver disease other than HCV (e.g., hemochromatosis, autoimmune hepatitis, alcoholic liver disease, toxin exposures).
  • Hypersensitivity to study drugs.
  • Participation in any other clinical trial within 30 days of entry into this protocol.
  • Treatment with any investigational drug within 30 days of entry into this protocol.
  • History or evidence of decompensated liver disease (Child-Pugh B/C) and a Child-Pugh score >5. Ascites, coagulopathy, hyperbilirubinemia, hepatic encephalopathy, or hypoalbuminemia and a Child-Pugh score >5 are conditions consistent with decompensated liver disease.
  • History or other evidence of bleeding from esophageal varices or other conditions consistent with decompensated liver disease.
  • Hepatocellular carcinoma (HCC) or α-Fetoprotein >50μg/l.
  • Patients with organ transplants other than cornea and hair transplant.
  • Therapy with any antisystemic or immunomodulatory treatment (including supra-physiologic doses of steroids or radiation) <6 months prior the first dose of study drug
  • Hemoglobinopathy (e.g. thalassemia) or any other cause of or tendency for hemolysis.
  • Any known preexisting medical condition that could interfere with the patient's participation in and completion of the study such as:
  • Preexisting psychiatric condition, especially depression, or a history of severe psychiatric disorder, such as major psychosis, suicidal ideation and/or suicidal attempts (based on a mandatory psychiatric advice).
  • CNS trauma or active seizure disorders requiring medication.
  • Significant cardiovascular dysfunction.
  • Poorly controlled diabetes mellitus.
  • Renal dysfunction, i.e. serum creatinine levels >1.5 times upper limit of normal.
  • Autoimmune diseases.
  • Evidence of severe retinopathy (e.g. CMV retinitis, macular degeneration).
  • Any medical condition requiring, or likely to require during the course of the study, chronic systemic administration of steroids.
  • Clinical gout.
  • Important substance abuse (alcohol >80 g/d, i.v. drugs etc.).
  • Active opportunistic infections.
  • Non-Hodgkin lymphoma or Hodgkin lymphoma.
  • Kaposi sarcoma.
  • Inability or unwillingness to provide informed consent or abide by the requirements of the study.
  • Male partners of pregnant women.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Switzerland
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT00310336
Other Study ID Numbers  ICMJE EKBB 37/06
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE University Hospital, Basel, Switzerland
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Markus H Heim, MD University Hospital, Basel, Switzerland
PRS Account University Hospital, Basel, Switzerland
Verification Date October 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP